Rutgers Cancer Institute of New Jersey
Rutgers Biomedical and Health Sciences New Brunswick, New Jersey
Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, was established in 1991, became an NCI-designated Cancer Center in 1997, achieved Comprehensive Cancer Center status in 2002 and was successfully re-designated in 2012. The Cancer Institute of New Jersey was elevated under the New Jersey Medical and Health Sciences Education Restructuring Act, and became an independent unit of Rutgers, The State University of New Jersey on July 1, 2013.
Rutgers Cancer Institute of New Jersey is dedicated to improving the prevention, detection, treatment, and care of patients with cancer, through the translation of laboratory discoveries into clinical practice. Its research base spans six key programmatic areas: Cell Death and Survival Signaling; Genomic Instability and Tumor Progression; Cancer Pharmacology and Preclinical Therapeutics; Clinical Investigations; Carcinogenesis and Chemoprevention; and Cancer Prevention and Control.
Highlights of the Cancer Institute’s research enterprise include a research consortium and collaboration with Princeton University and the Institute for Advanced Study, a Center for Systems Biology, and a precision medicine initiative.
The precision medicine initiative at the Cancer Institute explores gene abnormalities through targeted DNA analysis. While investigators aim to identify genomic changes and patterns that may possibly influence treatment outcomes in more common cancers, they are examining rare and poor prognosis cancers as well. Rapid assessment through Next Generation Sequencing enables researchers to put theory into practice almost immediately. Biomarkers that are discovered are discussed at a weekly meeting of the precision medicine molecular tumor board, comprised of clinicians, basic scientists, geneticists, systems biologists and those with computational expertise. The team then decides if the sequencing results suggest more ‘personalized’ therapy options, which could include enrollment in a clinical trial that is testing a novel drug.
Beyond New Jersey’s border, through Rutgers University, the Cancer Institute of New Jersey is now part of the Big Ten Cancer Research Consortium, which is comprised of universities whose athletic programs are part of the Big Ten Conference. Through a team-research culture, the Cancer Institute collaborates with other member institutions on developing clinical trials with a molecular diagnostic focus in order to improve the lives of cancer patients.
In 2008, the Cancer Institute took over the direction of the New Jersey State Cancer Registry. One of only 20 registries in 16 states designated and funded as part of the NCI Surveillance Epidemiology and End Results program (SEER), the collected cancer statistics serve as a local and national resource for epidemiologic studies into the causes, treatments and outcomes in patients with cancer.
Comprehensive treatment is provided by multidisciplinary teams of experts including oncologists, hematologists, nurses, pharmacists, social workers, nutritionists and others all under one roof to help educate patients so that they can make informed decisions about their care. Patients also have access to clinical trials and other services through the Cancer Institute of New Jersey’s Network of 16 hospitals across the state. Robert Wood Johnson University Hospital is the Flagship Hospital of the Cancer Institute of New Jersey.
* This profile was provided by the Cancer Institute of New Jersey.